BIOMEDICINE & PHARMACOTHERAPY
·
2022
·
IF 7.419
Li-hua Bian,Zi-wei Yao,Zhe-yi Wang,Xiao-mei Wang,Qiu-yu Li,Xue Yang,Jia-yuan Li,Xiao-jia Wei,Guo-hui Wan,Yu-qing Wang,Jin-li Shi,Jian-you Guo
In a rotenone-induced Parkinson’s disease (PD) rat model, behavioral investigation, pathological examination, inflammatory factor analysis, and mitochondrial structure and function investigation verified the anti-PD efficacy of nardosinone. A combined transcriptome and proteome analysis proposed that the anti-PD target of nardosinone is the slc38a2 gene and may involve the GABAergic synaptic pathway and cAMP-signaling pathway. Analysis of targeted slc38a2 knockout cells and expression of key enzyme-encoding genes in both pathways verified the target and pathways proposed by the ‘omics analysis. This further confirms that nardosinone can regulate the slc38a2 gene, a potential new target for the treatment of Parkinson's disease, and plays an anti-PD role through the GABAergic synaptic and cAMP pathways.
研究领域:
神经科学
·
药理学
·
分子生物学
·
基因组学
✓ 已验证
产品关联
DOI
PubMed
高影响因子
Alzheimers Research & Therapy
·
2026
·Vol. 18
·期 1
·66
·
IF 8.9
Lv Lifang,Jia Yuhan,Zhang Chi,Gao Qiang,Han Huiming,Li Jiaxin,Cai Zhenhua,Liu Meiqi,Zhang Ying,Liu Jinfeng,Zhu Hui
Background Ferroptosis has been implicated in the pathogenesis of Alzheimer’s disease (AD), yet its upstream neuronal regulators remain unclear. This study investigated the mechanisms by which melatonin exerts neuroprotection, focusing on the glutamine transporter solute carrier family 38 member 2 (SLC38A2), which inhibits ferroptosis in AD. Methods AD models included C57BL/6 mice injected intracerebroventricularly with beta-amyloid (Aβ) 1-42 oligomers, organotypic hippocampal slices treated with Aβ 1-42 oligomers, and HT22 hippocampal neurons treated with hydrogen peroxide. Cognition and hippocampal pathology were assessed by open field test, Morris water maze (MWM), shuttle box tests, and histology. Cross-species multi-omics comprised single-cell RNA sequencing of human hippocampus, mouse spatial transcriptomics, human bulk RNA sequencing and proteomics. Protein changes were measured by immunohistochemistry, immunofluorescence and Western blotting. Biochemical assays quantified glutathione (GSH), malondialdehyde (MDA), iron, and reactive oxygen species (ROS). Results In Aβ 1-42 oligomer-injected C57BL/6 mice, melatonin improved cognition in MWM and shuttle box tests without affecting locomotion, reduced hippocampal neuronal loss, and lowered Aβ/Tau/p-Tau. Single-cell RNA sequencing of human hippocampus and spatial transcriptomics in the mouse brain demonstrated pronounced ferroptosis in the AD hippocampal region. Integrative human proteomics, bulk RNA sequencing and spatial transcriptomics prioritized the downregulation of the glutamine-family amino-acid catabolic process and identified SLC38A2 as a key node. In vivo and in organotypic hippocampal slices, melatonin reversed the Aβ 1-42 oligomer-induced ferroptosis signature. Immunohistochemistry, immunofluorescence, and Western blotting showed that melatonin upregulated SLC38A2 in the Aβ-treated hippocampus and slices. Functionally, shRNA-mediated SLC38A2 knockdown in HT22 neurons reduced GSH and glutathione peroxidase 4 (GPX4), increased iron and ROS, enhanced erastin-induced ferroptosis, and abolished the protective effect of melatonin. Conclusions These findings identify SLC38A2 as a pivotal regulator of hippocampal ferroptosis and demonstrate that melatonin confers neuroprotection by stabilizing the SLC38A2-GSH-GPX4 axis, supporting SLC38A2 as a therapeutic target in AD.
✓ 已验证
DOI
高影响因子
危险品化学品经营许可证（带存储）